Allergy

At AAAAI 2026, Torres highlighted phase 3 peach immunotherapy research, nanostructure preclinical models, and a phase 2 prebiotic trial for LTP allergy.

At AAAAI 2026, Magerl discusses phase 2 data showing BW-20805 reduced hereditary angioedema attacks by up to 100% with dosing intervals of up to 6 months.

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.

At AAAAI 2026, Larenas-Linnemann discusses evidence, safety, and long-term benefits of sublingual immunotherapy for allergic rhinitis and asthma.

At AAAAI 2026, Nowak-Wegrzyn presented FPIES diagnosis in infants, emphasizing clinical recognition and updated oral food challenge protocols.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

Phase 2 ALPHA-SOLAR data presented at AAAAI 2026 show navenibart provides >95% median attack reduction in HAE with favorable safety for 3- and 6-month prophylaxis.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2026.

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

Shamji discussed the advantages of PQ grass over conventional immunotherapy at AAAAI 2026.

A randomized crossover study shows that most patients prefer intranasal epinephrine for anaphylaxis due to its ease of use, portability, and the absence of needles.

COMBINE trial data show dupilumab added to omalizumab-assisted OIT improved desensitization and reduced GI symptoms, despite no sustained response benefit.

Han discusses late-breaking phase 2 VIBRANT data at AAAAI 2026, which showed that quarterly TSLP receptor blockade reduced the need for CRSwNP by 76%.

Cogent Biosciences previously submitted an NDA for bezuclastinib at the end of 2025.

Akin discussed how avapritinib continues to demonstrate its benefit in indolent systematic mastocytosis.

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Early gut microbiome changes in c-section infants linked to food sensitization at 12 months, highlighting a potential critical intervention window.

Trial data show early microbiome shifts after vaginal microbial transfer in cesarean-delivered infants, with differences in food sensitization at 12 months.

HLA-A*32:01 carrier screening may identify patients at elevated risk for lamotrigine-induced eosinophilia and systemic symptoms, Krantz says at AAAAI 2026.

Prospective case-control data presented at AAAI 2026 demonstrate a 12-fold increased odds of DRESS among lamotrigine-treated HLA-A*32:01 carriers.

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy.

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.

Expert panel identifies high agreement for multi-organ involvement, but uncertainty remains in moderate isolated skin or mucosal symptoms.